CYNBIOSE
Votre contact :
CONTAMIN Hugues
CEO
06 62 74 35 66
Activités :
Cynbiose is a specialty CRO unique in Europe. The company is specialized in preclinical research services with a core expertise and focus on the non-human primate (NHP) model.
We provide hybrid exploratory designs, customized & high value-added services in a high quality-based GLP-like environment.
Our preclinical offer covers:
- Exploratory pharmacokinetics, central PK and pharmacodynamics studies
- Early safety studies, toxicokinetics and biodistribution studies
- Efficacy studies (PoC) in multiple therapeutic areas such as infectious and respiratory diseases, Central Nervous System, immune and inflammation disorders, ...
Our subsidiary, Cynbiose Respiratory, is a preclinical CRO specializing in respiratory diseases and aerosol therapies.
Our facility is AAALAC accredited since 2015 and we can operate studies from BSL 1 to 3. We have also developed unique capabilities in performing studies with ATMPs such as gene therapies containing GMOs (viral vectors, …).
Cynbiose is involved in several collaborative research projects with leading academic research teams and biopharmas, to develop new preclinical models and support progress in biomedical science.
Cynbiose also launched CYNBIOME, the 1st preclinical excellence network on microbiota and infectious diseases based on the Non-Human Primate (NHP) model.
Informations métier
Service(s)
- DMPK
- DMPK
- Pharmacodynamique
- Pharmacodynamics
- Pharmacologie
- Pharmacology
- Pharmacologie de sécurité
- Safety pharmacology
- Toxicologie / Toxicité
- Toxicology / Toxicity
Catégorie(s)
- Anti-corps MOA (mode d’action)
- Antibody MOA (mode of action)
- Anti-infectieux
- Anti infectious
- Biomarqueurs
- Biomarkers
- CNS
- CNS
- Découverte et analyse des biomarqueurs pour les essais cliniques
- Discovery and analysis of biomarkers for clinical trials
- Diabètes
- Diabetes
- DMPK
- DMPK
- Douleur et maladie inflammatoire
- Pain and inflammation disease
- Études de biodistribution
- Biodistribution studies
- Études/efficaces os et cartilage
- Bone and cartilage
- Gastro-entérologie
- Gastro enterology
- Immuno-inflammation
- Immuno inflammation
- Immunologie
- Immunology
- Immunotoxicité
- Immunotoxicity
- Inflammation
- Inflammation
- Maladie métabolique
- Metabolic disease
- Maladie neurodégénérative
- Neurodegenerative disease
- Maladie respiratoire
- Respiratory disease
- Maladies cardiovasculaires
- Cardiovascular diseases
- Maladies infectieuses
- Infectious diseases
- Maladies infectieuses
- Inflammatory diseases
- Maladies métaboliques et cardiovasculaires
- Metabolic and cardiovascular diseases
- Metabolic disesase
- Metabolic disesase
- Modèles de maladies métaboliques
- Metabolic diseases models
- Modèles in vivo
- In-vivo models
- Modèles précliniques
- Preclinical models
- Multi-indications
- Multi indications
- Neurologie
- Neurology
- Oncologie
- Oncology
- Pharmacocinétique
- Pharmacokinetics
- Pharmacologie
- Pharmacology
- PK-PD
- PK – PD
- Préclinique
- Preclinical
- Rhumatologie
- Rhumatology
- Sécurité préclinique
- Preclinical safety
- Services de consultation préclinique
- Preclinical consulting services
- Singe
- Monkey
- ToxicoKinetics
- ToxicoKinetics
- Toxicologie / toxicité / foie
- Liver toxicity
- Toxicologie préliminaire
- Preliminary toxicology
- Troubles métaboliques
- Metabolic disorders
- Vaccins anti-infectueux
- Anti-infectuous vaccines
- Validation de l’efficacité thérapeutique
- Therapeutic efficacy validation
Norme(s)
- AAALAC
- AAALAC
- CIR
- CIR
- GLP
- GLP
Innovation(s) Produit)
«
En cas d'erreur ou d'information incomplète, connectez-vous à votre compte membre, rubrique Mon profil CARTO
Ou en nous contactant à cartographie@afssi.fr. »